Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio, Color to Offer Combined Hereditary and Somatic Cancer Blood Test

NEW YORK (GenomeWeb) – Cynvenio Biosysterms and Color announced an agreement today to offer a combined version of their respective liquid biopsy and hereditary cancer tests.

Using the new offering, clinicians can test breast cancer patients for alterations in the 30 genes on Color's hereditary cancer panel, as well as for somatic cancer mutations in the 27 genes that Cynvenio's ClearID breast cancer test covers.

Color's test detects alterations in BRCA1 and BRCA2, as well as a number of other genes associated with increased risk of hereditary cancers, including melanoma, ovarian, colorectal, pancreatic, prostate, stomach, and uterine cancers. All tested patients and their healthcare providers gain access to board-certified genetic counselling.

Cynvenio's test analyzes both circulating tumor cells and cell-free DNA, and was designed for patients undergoing treatment for advanced breast cancer, or those who require follow-up at regular intervals after completing therapy.

The combined Color and ClearID test offers a comprehensive approach for assessing hereditary breast cancer risk and monitoring patients at risk of disease, the companies said.

"Even well into therapy, too many patients do not seek BRCA testing because of concerns over cost or other reasons, which is unfortunate because BRCA status is important for evaluating treatment strategies," Cynvenio CEO André de Fusco said in a statement.

De Fusco added that combining the two tests could also lower cost barriers and hopefully expand availability of BRCA and hereditary cancer testing to more people who could benefit from it.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.